OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

January 14th 2017

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer

January 14th 2017

Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.

Dr. Buffington Discusses Prostate Cancer Screening

January 13th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses effective prostate cancer screening methods and when to use active surveillance.

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

January 13th 2017

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Yardley on tNACity Trial for Triple-Negative Breast Cancer

January 12th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

Lori Sakoda on Genetic Risk Variants for COPD and Lung Cancer

January 12th 2017

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

January 12th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Dr. Albala on the Benefits of Robotic Surgery in Prostate Cancer

January 12th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses the benefits associated with robotic surgery in the treatment of patients with prostate cancer.

Dr. Goy on Combination Therapies in Mantle Cell Lymphoma

January 12th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combination therapies currently being explored in the treatment of patients with mantle cell lymphoma.

Dr. Rolfo on Precision Medicine in Lung Cancer

January 12th 2017

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Dr. Mamounas on Extended Letrozole Therapy for Breast Cancer

January 11th 2017

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

Dr. Chaudhary on History of CAR T-Cell Therapy

January 11th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

January 11th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses novel agents or clinical trials in development designed to help guide treatment decisions for patients with prostate cancer.

Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

January 11th 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Samuel Smith on Adherence in Menopausal Women at Risk for Breast Cancer

January 11th 2017

Samuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer

January 11th 2017

Hatem Soliman, MD, associate member of The Center for Women’s Oncology at the Moffitt Cancer Center discusses the prospective registry IMPACt study, which measured the impact of the MammaPrint 70-gene Breast Cancer Recurrence Assay in the routine management of women with early-stage breast cancer.

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

January 10th 2017

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Dr. Sklar on the Role of Nivolumab in Bladder Cancer

January 10th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.